Grünenthal Acquires Rights to Nebido From Bayer for Up to $503 Million

Bayer has sold off the rights to Nebido (testosterone undecanoate), its injectable treatment for testosterone deficiency, to Grünenthal for approximately $503 million.

The male hypogonadism treatment has patent exclusivity in the EU until March 2024 and in the U.S. until May 2027, although it is not sold in the U.S. However, the FDA approved Aveed, a similar drug from Endo Pharmaceuticals, in 2014.

One in six men over 50 have symptoms of testosterone deficiency, but too few of them receive appropriate treatment, said Grünenthal CEO Gabriel Baertschi.